| dc.contributor.author | Karaaslan, Zerrin | |
| dc.contributor.author | Kurtuncu, Murat | |
| dc.contributor.author | Akcay, Halil Ibrahim | |
| dc.contributor.author | Gunduz, Tuncay | |
| dc.contributor.author | Altunrende, Burcu | |
| dc.contributor.author | Turkoglu, Recai | |
| dc.contributor.author | Eraksoy, Mefkure | |
| dc.date.accessioned | 2022-01-29T16:52:18Z | |
| dc.date.available | 2022-01-29T16:52:18Z | |
| dc.date.issued | 2021 | |
| dc.identifier.issn | 0014-3022 | |
| dc.identifier.issn | 1421-9913 | |
| dc.identifier.uri | https://doi.org/10.1159/000517770 | |
| dc.identifier.uri | http://hdl.handle.net/11446/4421 | |
| dc.description.abstract | [No Abstract Availale] | en_US |
| dc.description.sponsorship | Novartis PharmaceuticalsNovartis | en_US |
| dc.description.sponsorship | This study was sponsored by Novartis Pharmaceuticals. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | Karger | en_US |
| dc.identifier.doi | 10.1159/000517770 | |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients | en_US |
| dc.type | letter | en_US |
| dc.relation.journal | European Neurology | en_US |
| dc.department | DBÜ | en_US |
| dc.relation.publicationcategory | Diğer | en_US |
| dc.department-temp | [Karaaslan, Zerrin; Ulusoy, Canan; Yilmaz, Vuslat; Tuzun, Erdem] Istanbul Univ, Aziz Sancar Inst Expt Med, Dept Neurosci, Istanbul, Turkey; [Kurtuncu, Murat; Akcay, Halil Ibrahim; Gunduz, Tuncay; Eraksoy, Mefkure] Istanbul Univ, Istanbul Fac Med, Dept Neurol, Istanbul, Turkey; [Altunrende, Burcu] Demiroglu Bilim Univ, Fac Med, Dept Neurol, Istanbul, Turkey; [Turkoglu, Recai] Istanbul Haydarpasa Numune Training & Res Hosp, Dept Neurol, Istanbul, Turkey | en_US |
| dc.authorid | ulusoy, canan/0000-0002-5599-4917 | |
| dc.authorwosid | Tuzun, Erdem/AAH-9212-2019 | |
| dc.authorwosid | ulusoy, canan/AAD-1681-2019 | |
